Source-grounded facts extracted from HYPERION DEFI, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HYPERION DEFI, INC. reported first quarter ending March 31, 2026 results: net income 8,840,550. Guidance raised.
“On May 14, 2026, Hyperion DeFi, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.”
HYPERION DEFI, INC.: Amended quorum requirement for stockholder meetings from simple majority to one-third; allowed written consent in lieu of meeting (effective 2026-03-20).
“On March 20, 2026, the Board of Directors (the “Board”) of the Company approved the Company’s Third Amended and Restated Bylaws (the “Restated Bylaws”). The Restated Bylaws provide that (i) the quorum requirement for stockholder meetings shall be one-third (1/3) of the shares of capital stock entitled to vote at such meetings, reduced from a simple majority, and (ii) any action required or permitted to be taken by the stockholders of the Company may be effected at a duly called annual or special meeting of the stockholders of the Company or by any consent in writing by such stockholders. The Restated Bylaws were effective upon adoption by the Board.”
HYPERION DEFI, INC. reported financial results for the fiscal year ended December 31, 2025.
“On March 26, 2026, Hyperion DeFi, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.”
HYPERION DEFI, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“September 2, 2025, the Company received a notice from the Staff indicating that the Company has regained compliance with the Minimum Equity Requirement.”
HYPERION DEFI, INC.: Filed Certificate of Designation for Series A Preferred Stock, establishing terms of a new series of preferred stock (effective 2025-06-20).
“On June 20, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations with the Secretary of State of the State of Delaware to provide for the designation of shares of the Series A Preferred Stock (the "Certificate of Designation"), which became effective upon filing.”
Ram Palanki resigned as Director at HYPERION DEFI, INC..
“On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.”
Charles Mather IV resigned as Chair at HYPERION DEFI, INC..
“On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.”
Sean Ianchulev resigned as Director at HYPERION DEFI, INC..
“On June 17, 2025, Sean Ianchulev, M.D., Charles Mather IV (Chair) and Ram Palanki, Pharm. D., resigned from the Board and their respective positions on the committees of the Board.”
Hyunsu Jung was appointed as Chief Investment Officer at HYPERION DEFI, INC..
“On June 17, 2025, the Board of Directors (the “Board”) of the Company appointed Hyunsu Jung to the position of Chief Investment Officer and to serve on the Board, effective immediately.”
HYPERION DEFI, INC. engaged CBIZ CPAs P.C. as its auditor.
“CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
Marcum LLP resigned as auditor of HYPERION DEFI, INC..
“Marcum resigned as the independent registered public accounting firm of Eyenovia, Inc. (the “Company”) and, with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
HYPERION DEFI, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 29, 2025, Eyenovia, Inc. (the “Company”) received a notice (the “Notice”) from the staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (the “Minimum Equity Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market, which continues to trade under the symbol “EYEN”. In accordance with”
HYPERION DEFI, INC. amended credit facility of $10.3 million in principal with Avenue Capital Management II, L.P., as administrative agent and collateral agent; Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P., as lenders at an annual rate equal to the greater of (a) 7.0% and (b) the prime rate as report maturing November 1, 2025.
“the Supplement, provides for term loans in an aggregate principal amount of up to $15.0 million to be delivered in multiple tranches. As of February 21, 2025, the Company owed $10.3 million in principal and accrued interest under the facility. Amounts outstanding under the facility bear interest at an annual rate equal to the greater of (a) 7.0% and (b) the prime”
HYPERION DEFI, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).
“December 12, 2024, the Company received a letter from Nasdaq notifying the Company that, as of December 11, 2024, the common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions of Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, Nasdaq has determined to delist the Company’s securities from The Nasdaq Capital Market, notwithstanding the Bid Price Cure Period, which is rendered unavailable by the Low Priced Stocks Rule. The Company has the right to appeal Nasdaq’s determination by Decemb”
Andrew D. Jones changed role as Chief Financial Officer, Treasurer and Secretary at HYPERION DEFI, INC..
“Andrew D. Jones transitioned out of his position as Chief Financial Officer, Treasurer and Secretary of the Company”
Andrew D. Jones was appointed as Chief Financial Officer, Treasurer and Secretary at HYPERION DEFI, INC..
“Also, effective August 30, 2024, the Board of Directors of the Company (the “Board”) appointed Andrew D. Jones to the positions of Chief Financial Officer, Treasurer and Secretary of the Company.”
John Gandolfo retired as Chief Financial Officer, Treasurer and Secretary at HYPERION DEFI, INC..
“John Gandolfo retired from his positions as Chief Financial Officer, Treasurer and Secretary of Eyenovia, Inc. (the “Company”).”
HYPERION DEFI, INC. reported the first quarter ended March 31, 2024 results: net income net loss was approximately $10.9 million, EPS $0.23 per share.
“For the first quarter of 2024, net loss was approximately $10.9 million, or $0.23 per share”
HYPERION DEFI, INC. entered into Purchase Agreement with a single fundamentals-based healthcare investor valued at approximately $2.0 million (effective 2024-04-08).
“On April 8, 2024, Eyenovia, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single fundamentals-based healthcare investor (the “Purchaser”)”
HYPERION DEFI, INC. entered into Letter Agreement with Bausch + Lomb Ireland Limited valued at cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo (effective 2024-01-12).
“On January 12, 2024, after successful negotiations between Eyenovia and B&L regarding the pediatric progressive myopia program, B&L and Eyenovia entered into a Letter Agreement (the “Letter Agreement”), pursuant to which Eyenovia will reacquire the rights to this program.”
HYPERION DEFI, INC. reported the third quarter ended September 30, 2023 results: net income approximately $(7.3) million, EPS $(0.18) per share.
“For the third quarter of 2023, net loss was approximately $(7.3) million, or $(0.18) per share compared to a net loss of approximately $(7.3) million, or $(0.21) per share, for the third quarter of 2022.”
Michael Geltzeiler was appointed as Director and Chair of Audit Committee at HYPERION DEFI, INC..
“On November 10, 2023, the Board of Directors (the “Board”) of the Company appointed Michael Geltzeiler to serve on the Board and as the Chair of the Audit Committee of the Board (the “Audit Committee”), in each case, effective November 14, 2023.”
HYPERION DEFI, INC. amended Warrant Amendment Agreement with the holder of previously issued warrants valued at amended Prior Warrants to reduce exercise price to $2.23 per share and extend term to March 1, 2029 (effective 2023-08-24).
“the Company entered into a warrant amendment agreement (the “Amendment”) with the holder (the “Holder”) of previously issued warrants (the “Prior Warrants”) to purchase up to 4,870,130 shares of Common Stock, whereby the Company agreed to amend the Prior Warrants to (i) reduce the exercise price of the Prior Warrants from $3.54 per share of Common Stock to $2.23 per share of Common Stock, (ii) extend the term of the Prior Warrants until March 1, 2029, (iii) include a stockholder approval requirement in connection with a modification of the beneficial ownership limitation contained in the Prior Warrants, and (iv) prohibit exercise of the Prior Warrants for the six-month period following the effective date of the Amendment, in each case, in accordance with the terms of the Amendment.”
HYPERION DEFI, INC. entered into Securities Purchase Agreement with a certain institutional and accredited investor valued at aggregate gross proceeds approximately $10.9 million (effective 2023-08-24).
“On August 24, 2023, Eyenovia, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional and accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the “Offering”), 4,198,633 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), pre-funded warrants to purchase up to 2,252,979 shares of Common Stock (the “Pre-Funded Warrants”) and warrants to purchase up to 4,838,709 shares of Common Stock (the “Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”).”
HYPERION DEFI, INC. entered into License Agreement with Formosa Pharmaceuticals, Inc. valued at $2 million within 45 days of the effective date of the agreement (effective 2023-08-15).
“On August 15, 2023, Eyenovia, Inc. (the “Company”), entered into a license agreement (the “License Agreement”) with Formosa Pharmaceuticals, Inc. (“Formosa”).”
HYPERION DEFI, INC. reported the second quarter ended June 30, 2023 results: net income approximately $(6.2) million, or $(0.16) per share, EPS $(0.16) per share.
“On August 10, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.”
HYPERION DEFI, INC. shareholders approved Ratification of the appointment of Marcum LLP as Eyenovia's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-27 meeting.
“3. Ratification of the appointment of Marcum LLP as Eyenovia’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
HYPERION DEFI, INC. shareholders approved Amendment to the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan to reserve an additional 1,000,000 shares of common stock for issuance at the 2023-06-27 meeting.
“2. Approval of an amendment to the Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan to reserve an additional 1,000,000 shares of common stock for issuance thereunder.”
HYPERION DEFI, INC. shareholders approved Election of directors to serve a one-year term expiring in 2024 at the 2023-06-27 meeting.
“1. Election of the following nominees of Eyenovia, to serve a one-year term expiring in 2024 or until their successors have been elected and qualified.”
HYPERION DEFI, INC. reported first quarter ended March 31, 2023 results: net income $(5.7) million, EPS $(0.15) per share.
“For the first quarter of 2023, net loss was approximately $(5.7) million, or $(0.15) per share”
HYPERION DEFI, INC. reported fiscal year ended December 31, 2022 results: net income net loss was approximately $[28.0] million, or $[0.83] per share on approximately 33.6 million weighted average shares o, EPS $[0.83] per share.
“For the full-year 2022, net loss was approximately $[28.0] million, or $[0.83] per share on approximately 33.6 million weighted average shares outstanding, and this compares to a net loss of approximately $[12.8] million, or $[0.49] per share, for the full year 2021 on approximately 26.3 million weighted average shares outstanding.”
HYPERION DEFI, INC. reported fourth quarter ended December 31, 2022 results: net income net loss was approximately $[6.1] million, or $[0.17] per share, EPS $[0.17] per share.
“For the fourth quarter of 2022, net loss was approximately $[6.1] million, or $[0.17] per share compared to a net income of approximately $3.0 million, or $0.11 per share, for the fourth quarter of 2021.”
Stephen Benjamin resigned as Director at HYPERION DEFI, INC..
“On February 28, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing the resignation of Stephen Benjamin from the Board of Directors (the “Board”) and the Audit Committee, effective as of February 27, 2023.”
Dr. Julia Haller resigned as Director at HYPERION DEFI, INC..
“In addition, the Company hereby announces the resignation of Dr. Julia Haller from the Board, effective as of December 6, 2022.”
Bren Kern was appointed as Chief Operating Officer at HYPERION DEFI, INC..
“On December 5, 2022, the Board of Directors (the “Board”) of Eyenovia, Inc. (the “Company”) appointed Bren Kern, the Company’s current Senior Vice President of Manufacturing and Operations, as the Company’s Chief Operating Officer, effective January 1, 2023.”
HYPERION DEFI, INC. incurred term loan of up to $15.0 million with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. at greater of (a) the sum of 4.45% and the prime rate as reported in The Wall Stree maturing November 1, 2025.
“Amount . The Loan and Security Agreement provides for term loans in an aggregate principal amount of up to $15.0 million to be delivered in multiple tranches (the “Term Loans”).”
HYPERION DEFI, INC. entered into Subscription Agreement with the Lenders (Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P.) (effective 2022-11-22).
“In connection with the entry into the Loan and Security Agreement, the Company entered into a Subscription Agreement by and among the Company and the Lenders, pursuant to which the Company issued (i) 219,123 shares of Common Stock to Avenue 1 and (ii) 328,684 shares of Common Stock to Avenue 2, with an issue date as of the Closing Date.”
HYPERION DEFI, INC. entered into Loan and Security Agreement with Avenue Capital Management II, L.P., as administrative agent and collateral agent, Avenue Venture Opportunities Fund II, L.P., as a lender, and Avenue Venture Opportunities Fund, L.P., as a lender valued at $15.0 million (effective 2022-11-22).
“On November 22, 2022, Eyenovia, Inc. (the “Company”), as borrower, entered into a Loan and Security Agreement, including the initial Supplement referenced therein (the “Loan and Security Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”), Avenue Venture Opportunities Fund II, L.P., as a lender (“Avenue 2”), and Avenue Venture Opportunities Fund, L.P., as a lender (“Avenue 1", and together with Avenue 2, the “Lenders”).”
HYPERION DEFI, INC. reported third quarter ended September 30, 2022 results: net income net loss was approximately $(7.3) million, or $(0.21) per share, EPS $(0.21) per share.
“Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
HYPERION DEFI, INC. terminated Loan and Security Agreement (SVB Loan Agreement) with Silicon Valley Bank valued at Payoff amount of $8.028 million, including prepayment fee of $0.15 million (effective 2022-11-02).
“On November 2, 2022, the Loan and Security Agreement, dated as of May 7, 2021 (the “SVB Loan Agreement”), by and between Eyenovia, Inc. (the “Company”) and Silicon Valley Bank (“SVB”), was terminated upon the receipt by SVB of a payoff amount of $8.028 million from the Company; provided that the Company continues to be bound by certain indemnification obligations under Section 11.3 of the SVB Loan Agreement.”
Michael Rowe was appointed as Director at HYPERION DEFI, INC..
“Mr. Rowe will also serve as a member of the Board, effective as of August 1, 2022”
Michael Rowe was appointed as Chief Executive Officer at HYPERION DEFI, INC..
“On July 26, 2022, the Board appointed Michael Rowe as the Company’s Chief Executive Officer.”
Dr. Ram Palanki was appointed as Director at HYPERION DEFI, INC..
“On July 1, 2022, the Board of Directors (the “Board”) of Eyenovia, Inc. (the “Company”) appointed Dr. Ellen R. Strahlman and Dr. Ram Palanki as members of the Board, effective immediately.”
Dr. Ellen R. Strahlman was appointed as Director at HYPERION DEFI, INC..
“On July 1, 2022, the Board of Directors (the “Board”) of Eyenovia, Inc. (the “Company”) appointed Dr. Ellen R. Strahlman and Dr. Ram Palanki as members of the Board, effective immediately.”
Kenneth B. Lee, Jr. was named as Lead Director at HYPERION DEFI, INC..
“Kenneth B. Lee, Jr., a current director, has been named to the position of Lea”
Stephen Benjamin was appointed as Director at HYPERION DEFI, INC..
“the Board appointed Rachel Jacobson and Stephen Benjamin as members of the Board, effective as of February 4, 2022”
Rachel Jacobson was appointed as Director at HYPERION DEFI, INC..
“the Board appointed Rachel Jacobson and Stephen Benjamin as members of the Board, effective as of February 4, 2022”
Ernest Mario departed as Director at HYPERION DEFI, INC..
“Ernest Mario, Ph.D., who had served on the Board since December 2014, stepped down from the Board on February 3, 2022 in connection with the Settlement Agreement.”
Fred Eshelman resigned as Chairman of the Eyenovia Board at HYPERION DEFI, INC..
“Dr. Fred Eshelman, who has served as Chairman of the Eyenovia Board since 2014, will step down from the Board by the end of 2021 to pursue other professional interests.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.